10-K/A: Ovid Therapeutics Files Amendment to 10-K to Include Part III Information
Form 10-K/A Amendment
Ovid Therapeutics files an amendment to its annual report to include information required by Items 10 through 14 of Part III, related to directors, executive officers, compensation, and corporate governance.
Summary
- Ovid Therapeutics Inc. is filing Amendment No. 1 to its Annual Report on Form 10-K to include information required by Items 10 through 14 of Part III.
- This amendment includes details about directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and principal accountant fees.
- The company's definitive proxy statement will not be filed within 120 days after the end of the fiscal year, necessitating this amendment.
- Item 15 of the Initial Filing has also been amended to reflect the filing of the new certifications of its principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- As of April 24, 2025, there were 71,109,514 shares of common stock outstanding.
Sentiment
Score: 6
Explanation: The document is a regulatory filing, so the sentiment is neutral. It provides necessary information about the company's governance and compensation structure.
Positives
- The company has adopted a Code of Business Conduct and Ethics applicable to all officers, directors, and employees.
- The Board has adopted Corporate Governance Guidelines to review and evaluate business operations and make independent decisions.
- The company maintains a 401(k) retirement plan for employees with matching contributions.
- The company has an Incentive Compensation Recoupment Policy (Clawback Policy) in place.
- The Board has determined that all directors, except the CEO, are independent within Nasdaq listing standards.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| President and Chief Operating Officer | NA | Margaret Alexander | September 2024 | Promotion |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Audit Committee Membership | Dr. Papadopoulos was appointed as a member of the Audit Committee. | March 2025 | Strengthens the committee with additional expertise. |
| Director Compensation | The annual base retainer for each non-employee director was increased to $45,000, the initial stock option grant amount was increased to 90,000 shares, and the annual stock option grant amount was increased to 45,000 shares. | January 1, 2025 | Aims to attract and retain qualified and experienced directors. |
Stakeholder Impact
- Shareholders are provided with detailed information about the company's governance, executive compensation, and ownership structure.
- Employees are affected by the company's compensation policies and benefit plans.
- Directors are impacted by changes in compensation and governance guidelines.
Key Dates
| Date | Description |
|---|---|
| March 25, 2015 | Date of signed Lundbeck agreement referenced in the definition of 'cause' in Dr. Levin's employment agreement. |
| June 5, 2015 | Date of the Executive Employment Agreement between the Registrant and Jeremy M. Levin. |
| May 4, 2017 | Effective date of the amended and restated employment agreement with Dr. Levin. |
| September 30, 2020 | Effective date of the employment agreement between the Company and Jeff Rona. |
| June 2, 2021 | Effective date of the Executive Employment Agreement between the Company and Jeff Rona. |
| September 9, 2024 | Effective date of the amended and restated employment agreement with Ms. Alexander. |
| December 31, 2024 | Fiscal year end date. |
| January 1, 2025 | Effective date of salary increases for Dr. Levin, Ms. Alexander, and Mr. Rona, and changes to non-employee director compensation policy. |
| March 2025 | Dr. Papadopoulos was appointed as a member of the Audit Committee. |
| April 24, 2025 | Date for director and executive officer information, and share ownership data. |
| April 30, 2025 | Date of report signature. |
Keywords
executive compensation, corporate governance, directors, officers, security ownership, related transactions, accountant fees, Ovid Therapeutics, Form 10-K, amendment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.